Novartis hopes its meningococcal B vaccine becomes first global one after Phase III
This article was originally published in Scrip
Novartis is on track to file its investigational vaccine against meningococcal B bacteria in Europe by year-end after the first Phase III trial of 4CMenB in infants met its primary endpoints. The study showed the vaccine induces robust immune responses against all vaccine antigens and can be co-administered with other routine infant vaccines. The data were presented at the International Pathogenic Neisseria Conference (IPNC) in Banff, Canada.